241 related articles for article (PubMed ID: 32749681)
1. Pharmacokinetics, safety, and activity of trabectedin as first-line treatment in elderly patients who are affected by advanced sarcoma and are unfit to receive standard chemotherapy: A phase 2 study (TR1US study) from the Italian Sarcoma Group.
Grosso F; D'Ambrosio L; Zucchetti M; Ibrahim T; Tamberi S; Matteo C; Rulli E; Comandini D; Palmerini E; Baldi GG; DeCensi A; Bergaglio M; Marra D; Marchesi E; Siri G; D'Incalci M; Grignani G
Cancer; 2020 Nov; 126(21):4726-4734. PubMed ID: 32749681
[TBL] [Abstract][Full Text] [Related]
2. Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group.
Grignani G; D'Ambrosio L; Pignochino Y; Palmerini E; Zucchetti M; Boccone P; Aliberti S; Stacchiotti S; Bertulli R; Piana R; Miano S; Tolomeo F; Chiabotto G; Sangiolo D; Pisacane A; Dei Tos AP; Novara L; Bartolini A; Marchesi E; D'Incalci M; Bardelli A; Picci P; Ferrari S; Aglietta M
Lancet Oncol; 2018 Oct; 19(10):1360-1371. PubMed ID: 30217671
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of trabectedin for patients with unresectable and relapsed soft-tissue sarcoma in Japan: A Japanese Musculoskeletal Oncology Group study.
Kobayashi H; Iwata S; Wakamatsu T; Hayakawa K; Yonemoto T; Wasa J; Oka H; Ueda T; Tanaka S
Cancer; 2020 Mar; 126(6):1253-1263. PubMed ID: 31825533
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of trabectedin in advanced soft tissue sarcoma: beyond lipo- and leiomyosarcoma.
De Sanctis R; Marrari A; Marchetti S; Mussi C; Balzarini L; Lutman FR; Daolio P; Bastoni S; Bertuzzi AF; Quagliuolo V; Santoro A
Drug Des Devel Ther; 2015; 9():5785-91. PubMed ID: 26604682
[TBL] [Abstract][Full Text] [Related]
5. Retrospective Analysis of Trabectedin Therapy for Soft Tissue Sarcoma.
Kawaguchi K; Nakano K; Urasaki T; Fukuda N; Taira S; Ono M; Tomomatsu J; Nishizawa M; Ae K; Matsumoto S; Takahashi S
In Vivo; 2019; 33(5):1609-1614. PubMed ID: 31471412
[TBL] [Abstract][Full Text] [Related]
6. Protocol for the 2ND-STEP study, Japan Clinical Oncology Group study JCOG1802: a randomized phase II trial of second-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib.
Endo M; Kataoka T; Fujiwara T; Tsukushi S; Takahashi M; Kobayashi E; Yamada Y; Tanaka T; Nezu Y; Hiraga H; Wasa J; Nagano A; Nakano K; Nakayama R; Hamada T; Kawano M; Torigoe T; Sakamoto A; Asanuma K; Morii T; Machida R; Sekino Y; Fukuda H; Oda Y; Ozaki T; Tanaka K
BMC Cancer; 2023 Mar; 23(1):219. PubMed ID: 36890471
[TBL] [Abstract][Full Text] [Related]
7. A randomized phase III trial comparing trabectedin to best supportive care in patients with pre-treated soft tissue sarcoma: T-SAR, a French Sarcoma Group trial.
Le Cesne A; Blay JY; Cupissol D; Italiano A; Delcambre C; Penel N; Isambert N; Chevreau C; Bompas E; Bertucci F; Chaigneau L; Piperno-Neumann S; Salas S; Rios M; Guillemet C; Bay JO; Ray-Coquard I; Haddag L; Bonastre J; Kapso R; Fraslin A; Bouvet N; Mir O; Foulon S
Ann Oncol; 2021 Aug; 32(8):1034-1044. PubMed ID: 33932507
[TBL] [Abstract][Full Text] [Related]
8. Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial.
Le Cesne A; Blay JY; Domont J; Tresch-Bruneel E; Chevreau C; Bertucci F; Delcambre C; Saada-Bouzid E; Piperno-Neumann S; Bay JO; Mir O; Ray-Coquard I; Ryckewaert T; Valentin T; Isambert N; Italiano A; Clisant S; Penel N
Lancet Oncol; 2015 Mar; 16(3):312-9. PubMed ID: 25680558
[TBL] [Abstract][Full Text] [Related]
9. Analysis of clinical factors associated with survival in patients with soft-tissue sarcoma receiving trabectedin.
Simetić L; Blažičević K; Ladenhauser T; Golčić M; Majnarić T; Herceg D
Anticancer Drugs; 2021 Nov; 32(10):1058-1066. PubMed ID: 34232944
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of trabectedin in elderly patients with sarcoma: subgroup analysis from a phase III, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma.
Jones RL; Demetri GD; Schuetze SM; Milhem M; Elias A; Van Tine BA; Hamm J; McCarthy S; Wang G; Parekh T; Knoblauch R; Hensley ML; Maki RG; Patel S; von Mehren M
Ann Oncol; 2018 Sep; 29(9):1995-2002. PubMed ID: 30084934
[TBL] [Abstract][Full Text] [Related]
11. Trabectedin for Advanced Soft Tissue Sarcoma: Ten Year Real-Life Perspective.
Shamai S; Merimsky O
Isr Med Assoc J; 2018 Oct; 20(10):599-603. PubMed ID: 30324774
[TBL] [Abstract][Full Text] [Related]
12. Trabectedin for inoperable or recurrent soft tissue sarcoma in adult patients: a retrospective cohort study.
Angarita FA; Cannell AJ; Abdul Razak AR; Dickson BC; Blackstein ME
BMC Cancer; 2016 Jan; 16():30. PubMed ID: 26786213
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of Elderly Patients with Advanced Soft Tissue Sarcoma Treated with First-Line Chemotherapy: A Pooled Analysis of 12 EORTC Soft Tissue and Bone Sarcoma Group Trials.
Younger E; Litière S; Le Cesne A; Mir O; Gelderblom H; Italiano A; Marreaud S; Jones RL; Gronchi A; van der Graaf WTA
Oncologist; 2018 Oct; 23(10):1250-1259. PubMed ID: 29650688
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide expanded access program study.
Samuels BL; Chawla S; Patel S; von Mehren M; Hamm J; Kaiser PE; Schuetze S; Li J; Aymes A; Demetri GD
Ann Oncol; 2013 Jun; 24(6):1703-9. PubMed ID: 23385197
[TBL] [Abstract][Full Text] [Related]
15. Time lapse analysis of tumor response in patients with soft tissue sarcoma treated with trabectedin: A pooled analysis of two phase II clinical trials.
Endo M; Takahashi S; Araki N; Sugiura H; Ueda T; Yonemoto T; Takahashi M; Morioka H; Hiraga H; Hiruma T; Kunisada T; Matsumine A; Goda K; Kawai A
Cancer Med; 2020 Jun; 9(11):3656-3667. PubMed ID: 32220056
[TBL] [Abstract][Full Text] [Related]
16. Trabectedin: Ecteinascidin 743, Ecteinascidin-743, ET 743, ET-743, NSC 684766.
Drugs R D; 2006; 7(5):317-28. PubMed ID: 16922593
[TBL] [Abstract][Full Text] [Related]
17. Trabectedin for metastatic soft tissue sarcoma: a retrospective single center analysis.
Schmitt T; Keller E; Dietrich S; Wuchter P; Ho AD; Egerer G
Mar Drugs; 2010 Oct; 8(10):2647-58. PubMed ID: 21116412
[TBL] [Abstract][Full Text] [Related]
18. Trabectedin use in soft-tissue sarcoma patients in a real-world setting: Data from an Italian national drug-access registry.
Vincenzi B; Napolitano A; Comandone A; Sanfilippo R; Celant S; Olimpieri PP; Di Segni S; Russo P; Casali PG
Int J Cancer; 2023 Feb; 152(4):761-768. PubMed ID: 36196483
[TBL] [Abstract][Full Text] [Related]
19. Trabectedin is a feasible treatment for soft tissue sarcoma patients regardless of patient age: a retrospective pooled analysis of five phase II trials.
Cesne AL; Judson I; Maki R; Grosso F; Schuetze S; Mehren MV; Chawla SP; Demetri GD; Nieto A; Tanovic A; Blay JY
Br J Cancer; 2013 Oct; 109(7):1717-24. PubMed ID: 24022187
[TBL] [Abstract][Full Text] [Related]
20. Trabectedin in advanced soft tissue sarcoma: case series.
Demirci U; Buyukberber S; Yetisyigit T; Dizdar O; Benekli M; Alkis N; Coskun U;
J BUON; 2012; 17(3):591-2. PubMed ID: 23033305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
